Lexiscan Approval History
- FDA approved: Yes (First approved April 10th, 2008)
- Brand name: Lexiscan
- Generic name: regadenoson
- Company: CV Therapeutics, Inc.
- Treatment for: Diagnosis and Investigation
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.
Development History and FDA Approval Process for Lexiscan
|Apr 11, 2008||CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(regadenoson) Injection|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.